World journal of gastroenterology · 2025
Risk factors and long-term prognosis for colorectal strictures in ulcerative colitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shao Yu-Pei, Han Tao-Tao, Lv Hong, Yang Sun-Ting, Zhu Qing-Li, Li Ji, Li Jing-Nan
Аннотация
BACKGROUND: Strictures in ulcerative colitis (UC) are relatively uncommon but are associated with increased risk of malignancy and complications. Until recently, fibrogenesis and strictures have remained largely unexplored in UC.
AIM: To investigate the incidence, long-term prognosis and risk factors of colorectal strictures in a large cohort of UC patients.
METHODS: A total of 938 hospitalized UC patients at Peking Union Medical College Hospital were included from 2014 to 2024. Stricture was defined as a fixed localized narrowing of the colorectal lumen. Risk factors for stricture formation were identified by multivariable Cox regression. Prognosis was analyzed using the Kaplan-Meier or Fine-Gray method. Sensitivity analysis excluded malignant strictures due to their distinct pathophysiology.
RESULTS: The overall incidence of stricture was 12.4% over a median follow-up of 8.70 years, with a 10-year cumulative probability of 11.3%. Malignancy occurred in 8.6% of stricture cases. UC patients with strictures were at higher risk for intestinal complications, surgery and malignancy (P < 0.05). The 10-year cumulative probabilities of surgery and all-cause mortality were 37.6% and 1.6%, respectively. Age ≥ 40 years at diagnosis [hazard ratio (HR) = 2.197, 95% confidence interval (CI): 1.487-3.242] and extraintestinal manifestations (HR = 2.072, 95%CI: 1.326-3.239) were associated with higher stricture risk, while the use of biological agents such as vedolizumab (HR = 0.382, 95%CI: 0.203-0.720) was protective against strictures (P < 0.05). Sensitivity analysis on benign strictures showed consistent findings, with similar risk factors and worse long-term outcomes.
CONCLUSION: UC patients with strictures had worse long-term prognostic outcomes. Earlier endoscopic surveillance and biologic treatment should be considered in patients ≥ 40 years or those with extraintestinal manifestations.
AIM: To investigate the incidence, long-term prognosis and risk factors of colorectal strictures in a large cohort of UC patients.
METHODS: A total of 938 hospitalized UC patients at Peking Union Medical College Hospital were included from 2014 to 2024. Stricture was defined as a fixed localized narrowing of the colorectal lumen. Risk factors for stricture formation were identified by multivariable Cox regression. Prognosis was analyzed using the Kaplan-Meier or Fine-Gray method. Sensitivity analysis excluded malignant strictures due to their distinct pathophysiology.
RESULTS: The overall incidence of stricture was 12.4% over a median follow-up of 8.70 years, with a 10-year cumulative probability of 11.3%. Malignancy occurred in 8.6% of stricture cases. UC patients with strictures were at higher risk for intestinal complications, surgery and malignancy (P < 0.05). The 10-year cumulative probabilities of surgery and all-cause mortality were 37.6% and 1.6%, respectively. Age ≥ 40 years at diagnosis [hazard ratio (HR) = 2.197, 95% confidence interval (CI): 1.487-3.242] and extraintestinal manifestations (HR = 2.072, 95%CI: 1.326-3.239) were associated with higher stricture risk, while the use of biological agents such as vedolizumab (HR = 0.382, 95%CI: 0.203-0.720) was protective against strictures (P < 0.05). Sensitivity analysis on benign strictures showed consistent findings, with similar risk factors and worse long-term outcomes.
CONCLUSION: UC patients with strictures had worse long-term prognostic outcomes. Earlier endoscopic surveillance and biologic treatment should be considered in patients ≥ 40 years or those with extraintestinal manifestations.